Population pharmacokinetic/pharmacodynamic model of LY06006 in Chinese healthy subjects and postmenopausal osteoporotic women.
Yun Kuang, Ya-Xin Liu, Yan-Ni Teng, Lin-Feng Zhang, Jie Huang, Qi Pei, Cheng-Xian Guo, Jin-Fu Peng, Guo-Ping Yang
Br J Clin Pharmacol 92(2) 495-503
摘要
摘要
AIMS: LY06006, a biosimilar of denosumab, is a recombinant fully human monoclonal antibody targeting the receptor activator of nuclear factor κB ligand. LY06006 has completed Phase I and Phase III clinical studies. The objective of this study is to develop a pharmacokinetic (PK)/pharmacodynamic (PD) model of LY06006 in healthy male and osteoporotic female populations in China. METHODS: In total, 420 subjects were enrolled in this study, including 84 healthy male subjects from the Phase I study and 336 osteoporotic postmenopausal women from the Phase III study. A nonlinear mixed-effects model was used for model development. The free serum concentration of LY06006 was used for PK analysis, and Type 1 collagen C-terminal telopeptide was used for PD analysis. RESULTS: A two-compartment Michaelis-Menten approximate model was used to describe the PK profiles of LY06006. Body weight was a significant covariate for the volume of distribution of the central compartment (V1) and clearance. The estimated values of V1 in postmenopausal women with osteoporosis were 0.87×, those observed in healthy male subjects. The indirect effect model was used to describe PK/PD relationship. Subjects' height significantly influenced the baseline values of C-terminal telopeptide. CONCLUSION: A population PK/PD model was developed in Chinese healthy male subjects and postmenopausal osteoporotic women. A 60-mg dose of LY06006 achieves similar PD efficacy to denosumab. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry (https://www.chictr.org.cn/): ChiCTR2000039637, ChiCTR2000032882.
KM 提取结果
0 个 Figure · 0 个 KM 面板